Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis

Frontiers in Neurology

Volumn JAN, Issue , 2012, Pages

  Clos, Audra L ^a   Kayed, Rakez ^b   Lasagna Reeves, Cristian A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Amyloid; Brain and neurodegenerative amyloidosis; Skin

Indexed keywords

EID: 84865852333     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2012.00005     Document Type: Article

References (145)

1. Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., and Oda, T. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lat-eral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611.
2. Arck, P. C., Handjiski, B., Peters, E. M., Peter, A. S., Hagen, E., Fischer, A., Klapp, B. F., and Paus, R. (2003). Stress inhibits hair growth in mice by induc-tion of premature catagen devel-opment and deleterious perifollic-ular inflammatory events via neu-ropeptide substance P-dependent pathways. Am. J. Pathol. 162, 803-814.
3. Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., and Suzuki, N. (1995). Long amyloid beta-protein secreted from wild-type human neuroblas-toma IMR-32 cells. Biochemistry 34, 10272-10278.
4. Azriel, R., and Gazit, E. (2001). Analysis of the minimal amyloid-forming fragment of the islet amy-loid polypeptide. An experimen-tal support for the key role of the phenylalanine residue in amy-loid formation. J. Biol. Chem. 276, 34156-34161.
5. Beach, R. L., Rao, J. S., Festoff, B. W., Reyes, E. T., Yanagihara, R., and Gaj-dusek, D. C. (1986). Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 72, 49-60.
6. Beignon, A. S., Brown, F., Eftekhari, P., Kramer, E., Briand, J. P., Muller, S., and Partidos, C. D. (2005). A peptide vaccine adminis-tered transcutaneously together with cholera toxin elicits potent neutralis-ing anti-FMDV antibody responses. Vet. Immunol. Immunopathol. 104, 273-280.
7. Bhak, G., Choe, Y. J., and Paik, S. R. (2009a). Mechanism of amyloidoge-nesis: nucleation-dependent fibrilla-tion versus double-concerted fibril-lation. BMB Rep. 42, 541-551.
8. Bhak, G., Lee, J. H., Hahn, J. S., and Paik, S. R. (2009b). Granular assembly of alpha-synuclein leading to the accel-erated amyloid fibril formation with shear stress. PLoS ONE 4, e4177. doi:10.1371/journal.pone.0004177
9. Bhat, A., Selmi, C., Naguwa, S. M., Cheema, G. S., and Gershwin, M. E. (2009). Currents concepts on the immunopathology of amyloido-sis. Clin. Rev. Allergy Immunol. 38, 97-106.
10. Biro, T., Ko, M. C., Bromm, B., Wei, E. T., Bigliardi, P., Siebenhaar, F., Hashizume, H., Misery, L., Bergasa, N. V., Kamei, C., Schouenborg, J., Roostermann, D., Szabó, T., Maurer, M., Bigliardi-Qi, M., Meingassner, J. G., Hossen, M. A., Schmelz, M., and Steinhoff, M. (2005). How best to fight that nasty itch from new insights into the neuroimmunolog-ical, neuroendocrine, and neuro-physiological bases of pruritus to novel therapeutic approaches. Exp. Dermatol. 14, 225-240.
11. Black, M. M. (1971). The role of the epidermis in the histopathogenesis of lichen amyloidosis. Histochemi-cal correlations. Br. J. Dermatol. 85, 524-530.
12. Black, M. M., and Jones, E. W. (1971). Macular amyloidosis. A study of 21 cases with special reference to the role of the epidermis in its histogen-esis. Br. J. Dermatol. 84, 199-209.
13. Blesa, R., Ballard, C., Orgogozo, J. M., Lane, R., and Thomas, S. K. (2007). Caregiver preference for rivastig-mine patches versus capsules for the treatment of Alzheimer disease. Neurology 69, S23-S28.
14. Bongioanni, P., Reali, C., and Sogos, V. (2004). Ciliary neurotrophic fac-tor (CNTF) for amyotrophic lat-eral sclerosis/motor neuron dis-ease. Cochrane Database Syst. Rev. CD004302.
15. Bonnefont-Rousselot, D., Lehmann, E., Jaudon, M. C., Delattre, J., Perrone, B., and Rechke, J. P. (2000). Blood oxidative stress and lipoprotein oxi-dizability in haemodialysis patients: effect of the use of a vitamin E-coated dialysis membrane. Nephrol. Dial. Transplant. 15, 2020-2028.
16. Borasio, G. D., Robberecht, W., Leigh, P. N., Emile, J., Guiloff, R. J., Jerusalem, F., Silani, V., Vos, P. E., Wokke, J. H., and Dobbins, T. (1998). A placebo-controlled trial of insulin-like growth factor-I in amy-otrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583-586.
17. Botelho, M. G., and Lupi, O. (2008). Protein folding and cutaneous diseases. Int. J. Dermatol. 47, 1225-1233.
18. Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
19. Brownstein, M. H., and Helwig, E. B. (1970). The cutaneous amyloidosis. I. Localized forms. Arch. Dermatol. 102, 8-19.
20. Bucciantini, M., Calloni, G., Chiti, F., Formigli, L., Nosi, D., Dobson, C. M., and Stefani, M. (2004). Prefibril-lar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279, 31374-31382.
21. Cecchi, C., Fiorillo, C., Sorbi, S., Lator-raca, S., Nacmias, B., Bagnoli, S., Nassi, P., and Liguri, G. (2002). Oxidative stress and reduced antiox-idant defenses in peripheral cells from familial Alzheimer's patients. Free Radic. Biol. Med. 33,1372-1379.
22. Chiti, F., and Dobson, C. M. (2006). Protein misfolding, functional amy-loid, and human disease. Annu. Rev. Biochem. 75, 333-366.
23. Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., and Dobson, C. M. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fib-rils. Proc. Natl. Acad. Sci. U.S.A. 96, 3590-3594.
24. Citron, M. (2002). Alzheimer's disease: treatments in discovery and devel-opment. Nat. Neurosci. 5(Suppl.), 1055-1057.
25. Clos, A. L., Role of oligomers Lasagna-Reeves, C. A., Kelly, B., Wagner, R., Wilkerson, M., Jackson, G. R., and Kayed, R. (2011). Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. J. Am. Acad. Dermatol. 65, 1023-1031.
26. Clos, A. L., Lasagna-Reeves, C. A., Wag-ner, R., Kelly, B., Jackson, G. R., and Kayed, R. (2010). Therapeu-tic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. Exp. Dermatol. 19, 904-911.
27. Cohen, A. S. (1993). Primary (AL) amy-loidosis. Ren. Fail. 15, 429-433.
28. Daoud, H., Valdmanis, P. N., Kabashi, E., Dion, P., Dupré, N., Camu, W., Meininger, V., and Rouleau, G. A. (2009). Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet. 46, 112-114.
29. Davidson, Y., Kelley, T., Mackenzie, I. R., Pickering-Brown, S., Du Plessis, D., Neary, D., Snowden, J. S., and Mann, D. M. (2007). Ubiquiti-nated pathological lesions in fron-totemporal lobar degeneration con-tain the TAR DNA-binding pro-tein, TDP-43. Acta Neuropathol. 113, 521-533.
30. Dell, K., Koesters, R., Linnebacher, M., Klein, C., and Gissmann, L. (2006). Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24, 2238-2247.
31. Deng, H. X., Hentati, A., Tainer, J. A., Iqbal, Z., Cayabyab, A., Hung, W. Y., Getzoff, E. D., Hu, P., Herzfeldt, B., Roos, R. P., et al. (1993). Amy-otrophic lateral sclerosis and struc-tural defects in Cu, Zn superoxide dismutase. Science 261, 1047-1051.
32. Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Klos, K. J., and Ahlskog, J. E. (2009). Neuropathology of non-motor fea-tures of Parkinson disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S1-S5.
33. Dion, P. A., Daoud, H., and Rouleau, G. A. (2009). Genetics of motor neuron disorders: new insights into patho-genic mechanisms. Nat. Rev. Genet. 10, 769-782.
34. Duffy, D. L., Zhao, Z. Z., Sturm, R. A., Hayward, N. K., Martin, N. G., and Montgomery,G. W. (2010). Multiple pigmentation gene polymorphisms account for a substantial propor-tion of risk of cutaneous malignant melanoma. J. Invest. Dermatol. 130, 520-528.
35. Editorial. (2010). How much is demen-tia care worth? Lancet Neurol. 9, 1037.
36. Emre, M., Cummings, J. L., and Lane, R. M. (2007). Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J. Alzheimers Dis. 11, 509-519.
37. Epstein, E. A., and Chapman, M. R. (2008). Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres. Cell. Microbiol. 10, 1413-1420.
38. Eto, H., Hashimoto, K., Kobayashi, H., Fukaya, T., Matsumoto, M., and Sun, T. T. (1984). Differential staining of cytoid bodies and skin-limited amyloids with monoclonal anti-keratin antibodies. Am. J. Pathol. 116, 473-481.
39. Fang, L., Huber-Abel, F., Teuchert, M., Hendrich, C., Dorst, J., Schattauer, D., Zettlmeissel, H., Wlaschek, M., Scharffetter-Kochanek, K., Tumani, H., Ludolph, A. C., and Brettschnei-der, J. (2009). Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 285, 62-66.
40. Fang, L., Teuchert, M., Huber-Abel, F., Schattauer, D., Hendrich, C., Dorst, J., Zettlmeissel, H., Wlaschek, M., Scharffetter-Kochanek, K., Kapfer, T., Tumani, H., Ludolph, A. C., and Brettschneider, J. (2010). MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J. Neurol. Sci. 294, 51-56.
41. Feito-Rodriguez, M., Garcia-Macarron, J., Pagán-Muñoz, B., Mariño-Enríquez, A., Vidaurrázaga-Díaz, Y., Arcaya, C., Díaz-Díaz, R. M., and Casado-Jiménez, M. (2008). Disseminated nodular primary localized cutaneous amyloidosis. Actas Dermosifiliogr. 99, 648-652.
42. Fortune, D. G., Richards, H. L., and Griffiths, C. E. (2005). Psycho-logical factors in psoriasis: conse-quences, mechanisms, and interven-tions. Dermatol. Clin. 23, 681-694.
43. Fortune,D. G.,Richards,H. L.,Griffiths, C. E., and Main, C. J. (2002). Psycho-logical stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alex-ithymia. Br. J. Clin. Psychol. 41(Pt 2), 157-174.
44. Fowler, D. M., Koulov, A. V., Balch, W. E., and Kelly,J.W. (2007). Functional amyloid from bacteria to humans. Trends Biochem. Sci. 32, 217-224.
45. Fu, X., Korenaga, T., Fu, L., Xing, Y., Guo, Z., Matsushita, T., Hosokawa, M., Naiki, H., Baba, S., Kawata, Y., Ikeda, S., Ishihara, T., Mori, M., and Higuchi, K. (2004). Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils. FEBS Lett. 563, 179-184.
46. Furukawa, T., and Toyokura, Y. (1976). Letter: amyotrophic lateral sclerosis and bedsores. Lancet 1, 862.
47. Galuske, R. A., Drach, L. M., Nichtweiss, M., Marquardt, G., Franz, K., Bohl, J., and Schlote, W. (2004). Colo-calization of different types of amyloid in the walls of cerebral blood vessels of patients suffering from cerebral amyloid angiopathy and spontaneous intracranial hem-orrhage: a report of 5 cases. Clin. Neuropathol. 23, 113-119.
48. Geser, F., Martinez-Lage, M., Kwong, L. K., Lee, V. M., and Trojanowski, J. Q. (2009). Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J. Neurol. 256, 1205-1214.
49. Giasson, B. I., Lee, V. M., and Tro-janowski, J. Q. (2003). Interactions of amyloidogenic proteins. Neuromolecular Med. 4, 49-58.
50. Gitcho,M. A.,Baloh,R. H.,Chakraverty, S., Mayo, K., Norton, J. B., Levitch, D., Hatanpaa, K. J., White, C. L. III, Bigio, E. H., Caselli, R., Baker, M., Al-Lozi, M. T., Morris, J. C., Pestronk, A., Rademakers, R., Goate, A. M., and Cairns, N. J. (2008). TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 63, 535-538.
51. Giudice, E. L., and Campbell, J. D. (2006). Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58, 68-89.
52. Glabe, C. G. (2006). Common mech-anisms of amyloid oligomer patho-genesis in degenerative disease. Neurobiol. Aging 27, 570-575.
53. Glabe, C. G., and Kayed, R. (2006). Common structure and toxic func-tion of amyloid oligomers implies a common mechanism of pathogene-sis. Neurology 66(Suppl. 1),S74-S78.
54. Greenwald, J., and Riek, R. (2010). Biology of amyloid: structure, func-tion, and regulation. Structure 18, 1244-1260.
55. Gros-Louis, F., Gaspar, C., and Rouleau, G.A. (2006). Genetics of familial and sporadic amyotrophic lateral scle-rosis. Biochim. Biophys. Acta 1762, 956-972.
56. Gudbjartsson, D. F., Sulem, P., Stacey, S. N., Goldstein, A. M., Rafnar, T., Sigurgeirsson, B., Benediktsdot-tir, K. R., Thorisdottir, K., Ragnars-son, R., Sveinsdottir, S. G., Mag-nusson, V., Lindblom, A., Kostu-las, K., Botella-Estrada, R., Soriano, V., Juberías, P., Grasa, M., Saez, B., Andres, R., Scherer, D., Rudnai, P., Gurzau, E., Koppova, K., Kiemeney, L. A., Jakobsdottir, M., Steinberg, S., Helgason, A., Gretarsdottir, S., Tucker, M. A., Mayordomo, J. I., Nagore, E., Kumar, R., Hansson, J., Olafsson, J. H., Gulcher, J., Kong, A., Thorsteinsdottir, U., and Stefans-son, K. (2008). ASIP and TYR pig-mentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886-891.
57. Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D., and Dobson, C. M. (1998). Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. U.S.A. 95, 4224-4228.
58. Halaban,R.,Cheng,E.,Zhang,Y.,Moell-mann, G., Hanlon, D., Michalak, M., Setaluri, V., and Hebert, D. N. (1997). Aberrant retention of tyrosinase in the endoplasmic retic-ulum mediates accelerated degra-dation of the enzyme and con-tributes to the dedifferentiated phe-notype of amelanotic melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 94, 6210-6215.
59. Halevy, S., and Livni, E. (1993). Beta-adrenergic blocking drugs and pso-riasis: the role of an immunologic mechanism. J. Am. Acad. Dermatol. 29, 504-505.
60. Harper, J. D., and Lansbury, P. T. Jr. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407.
61. Hashimoto, K., and Kobayashi, H. (1980). Histogenesis of amyloid in the skin. Am. J. Dermatopathol. 2, 165-171.
62. Hashimoto, K., and Kumakiri, M. (1979). Colloid-amyloid bodies in PUVA-treated human psoriatic patients. J. Invest. Dermatol. 72, 70-80.
63. Hebert, L. E., Beckett, L. A., Scherr, P. A., and Evans, D. A. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 15, 169-173.
64. Herczenik, E., and Gebbink, M. F. (2008). Molecular and cellular aspects of protein misfolding and disease. FASEB J. 22, 2115-2133.
65. Hirano, A. (1991). Cytopathology of amyotrophic lateral sclerosis. Adv. Neurol. 56, 91-101.
66. Husby, G. (1992). Nomenclature and classification of amyloid and amyloi-doses. J. Intern. Med. 232, 511-512.
67. Iconomidou, V. A., and Hamodrakas, S. J. (2008). Natural protective amy-loids. Curr. Protein Pept. Sci. 9, 291-309.
68. Itoh, T., and Celis, E. (2005). Transcu-taneous immunization with cyto-toxic T-cell peptide epitopes pro-vides effective antitumor immunity in mice. J. Immunother. 28, 430-437.
69. Jang, H., Boltz, D., Sturm-Ramirez, K., Shepherd, K. R., Jiao, Y., Webster, R., and Smeyne, R. J. (2009). Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 14063-14068.
70. Jarrett, J. T., and Lansbury, P. T. Jr. (1993). Seeding " one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
71. Jarvikallio, A., Harvima, I. T., and Naukkarinen, A. (2003). Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch. Dermatol. Res. 295, 2-7.
72. Kalman, J., Szakacs, R., Török, T., Rózsa, Z., Barzó, P., Rudas, L., Papp, J. G., and Janka, Z. (2002). Decreased cutaneous vasodilatation to isomet-ric handgrip exercise in Alzheimer's disease. Int. J. Geriatr. Psychiatry 17, 371-374.
73. Kato, S. (2008). Amyotrophic lateral sclerosis models and human neu-ropathology: similarities and dif-ferences. Acta Neuropathol. 115, 97-114.
74. Katsikas, G. A., Maragou, M., Ron-togianni, D., Gouma, P., Koutsou-velis, I., and Kappou-Rigatou, I. (2008). Secondary cutaneous nodu-lar AA amyloidosis in a patient with primary Sjogren syndrome and celiac disease. J. Clin. Rheumatol. 14, 27-29.
75. Khalil, Z., LoGiudice, D., Khodr, B., Maruff, P., and Masters, C. (2007). Impaired peripheral endothelial microvascular responsiveness in Alzheimer's disease. J. Alzheimers Dis. 11, 25-32.
76. Kobayashi, H., and Hashimoto, K. (1983). Amyloidogenesis in organ-limited cutaneous amyloidosis: an antigenic identity between epider-mal keratin and skin amyloid. J. Invest. Dermatol. 80, 66-72.
77. Kolde, G., Bachus, R., and Ludolph, A. C. (1996). Skin involvement in amy-otrophic lateral sclerosis. Lancet 347, 1226-1227.
78. Kumakiri, M., and Hashimoto, K. (1979). Histogenesis of primary localized cutaneous amyloidosis: sequential change of epidermal ker-atinocytes to amyloid via filamen-tous degeneration. J. Invest. Dermatol. 73, 150-162.
79. Kvetnoi, I. M., Kvetnaia, T. V., Riad-nova,I. I. U.,Fursov,B. B.,Ernandes-Jago, H., and Blesa, J. R. (2003). Expression of beta-amyloid and tau-protein in mastocytes in Alzheimer disease. Arkh. Patol. 65, 36-39.
80. Kyle, R. A., and Gertz, M. A. (1990). Sys-temic amyloidosis. Crit. Rev. Oncol. Hematol. 10, 49-87.
81. Lai, E. C., Felice, K. J., Festoff, B. W., Gawel, M. J., Gelinas, D. F., Kratz, R., Murphy, M. F., Natter, H. M., Norris, F. H., and Rudnicki, S. A. (1997). Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The NorthAmerica ALS/IGF-I Study Group. Neurology 49, 1621-1630.
82. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R., and Kayed, R. (2010). Preparation and characteri-zation of neurotoxic tau oligomers. Biochemistry 49, 10039-10041.
83. Leigh, P. N., and Swash, M. (1991). Cytoskeletal pathology in motor neuron diseases. Adv. Neurol. 56, 115-124.
84. Lopez De La Paz, M., Goldie, K., Zurdo, J., Lacroix, E., Dobson, C. M., Hoenger, A., and Serrano, L. (2002). De novo designed peptide-based amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 99, 16052-16057.
85. Lorenzl, S., Narr, S., Angele, B., Krell, H. W., Gregorio, J., Kiaei, M., Pfister, H. W., and Beal, M. F. (2006). The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Exp. Neurol. 200, 166-171.
86. Maier, M., Seabrook, T. J., Lazo, N. D., Jiang, L., Das, P., Janus, C., and Lemere,C.A. (2006). Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26, 4717-4728.
87. Maier, M., Seabrook, T. J., and Lemere, C. A. (2005). Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B sub-unit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23, 5149-5159.
88. Maji, S. K., Perrin, M. H., Sawaya, M. R., Jessberger, S.,Vadodaria, K., Riss-man, R. A., Singru, P. S., Nilsson, K. P., Simon, R., Schubert, D., Eisen-berg, D., Rivier, J., Sawchenko, P., Vale, W., and Riek, R. (2009). Func-tional amyloids as natural storage of peptide hormones in pituitary secre-tory granules. Science 325, 328-332.
89. Matsumoto, S., Kusaka, H., Ito, H., Shibata, N., Asayama, T., and Imai, T. (1996). Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy body-like inclusions. Clin. Neuropathol. 15, 41-46.
90. Maurer-Stroh, S., Debulpaep, M., Kuemmerer, N., Lopez de la Paz, M., Martins, I. C., Reumers, J., Morris, K. L., Copland, A., Serpell, L., Serrano, L., Schymkowitz, J. W., and Rousseau, F. (2010). Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat. Methods 7, 237-242.
91. Meersman, F., Dobson, C. M., and Here-mans, K. (2006). Protein unfolding, amyloid fibril formation and config-urational energy landscapes under high pressure conditions. Chem. Soc. Rev. 35, 908-917.
92. Mercier, F., Lefevre, G., Huang, H. L., Schmidli, H., Amzal, B., and Appel-Dingemanse, S. (2007). Rivastig-mine exposure provided by a trans-dermal patch versus capsules. Curr. Med. Res. Opin. 23, 3199-3204.
93. Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Good-pasture, J. C., Hoagland, R. J., Parry, G. J., Ross, M. A., and Stromatt, S. C. (1996). A placebo-controlled trial of recombinant human ciliary neu-rotrophic (rhCNTF) factor in amy-otrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39, 256-260.
94. Mitchell,J. D.,Wokke,J. H.,and Borasio, G. D. (2007). Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclero-sis/motor neuron disease. Cochrane Database Syst. Rev. CD002064.
95. Miyazono, M., Kitamoto, T., Iwaki, T., and Tateishi, J. (1992). Colocaliza-tion of prion protein and beta pro-tein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol. 83, 333-339.
96. Morrison, B. M., and Morrison, J. H. (1999).Amyotrophic lateral sclerosis associated with mutations in super-oxide dismutase: a putative mech-anism of degeneration. Brain Res. Brain Res. Rev. 29, 121-135.
97. Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen,A. Ø., Riekel, C., Grothe, R., and Eisenberg, D. (2005). Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773-778.
98. Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Mic-senyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feld-man, H., Feiden, W., Kretzschmar, H. A., Trojanowski, J. Q., and Lee, V. M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
99. Nikolic,W. V., Bai,Y., Obregon, D., Hou, H.,Mori,T.,Zeng,J.,Ehrhart,J.,Shy-tle, R. D., Giunta, B., Morgan, D., Town, T., and Tan, J. (2007). Tran-scutaneous beta-amyloid immu-nization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. U.S.A. 104, 2507-2512.
100. Nitti, V. W., Sanders, S., Staskin, D. R., Dmochowski, R. R., Sand, P. K., MacDiarmid, S., and Maibach, H. I. (2006). Transdermal delivery of drugs for urologic applications:basic principles and applications. Urology 67, 657-664.
101. Okada, A., Urakami, K., Takahashi, K., Ohno, K., Sato, K., and Endo, H. (1994). Expression of amy-loid beta-protein precursor mRNAs in cultured skin fibroblasts taken from patients with dementia of the Alzheimer type. Dementia 5, 55-56.
102. Ono, S., Imai, T., Aso, A., Yamano, T., Shimizu, N., and Nagao, K. (1998a). Alterations of skin glycosaminogly-cans in patients with ALS. Neurology 51, 399-404.
103. Ono, S., Imai, T., Takahashi, K., Jinnai, K., Yamano, T., Nagao, K., Shimizu, N., and Yamauchi, M. (1998b). Decreased type IV collagen of skin and serum in patients with amy-otrophic lateral sclerosis. Neurology 51, 114-120.
104. Paisan-Ruiz, C., Bhatia, K. P., Li,A., Her-nandez, D., Davis, M., Wood, N. W., Hardy, J., Houlden, H., Singleton, A., and Schneider, S. A. (2009). Charac-terization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65, 19-23.
105. Paris, I., Dagnino-Subiabre, A., Marce-lain, K., Bennett, L. B., Caviedes, P., Caviedes,R.,Azar,C. O.,and Segura-Aguilar, J. (2001). Copper neuro-toxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neu-ronal cell line. J. Neurochem. 77, 519-529.
106. Pastor, M. T., Kummerer, N., Schubert, V., Esteras-Chopo, A., Dotti, C. G., López de la Paz, M., and Serrano, L. (2008). Amyloid toxicity is inde-pendent of polypeptide sequence, length and chirality. J. Mol. Biol. 375, 695-707.
107. Peters, E. M., Handjiski, B., Kuhlmei, A., Hagen, E., Bielas, H., Braun, A., Klapp, B. F., Paus, R., and Arck, P. C. (2004). Neurogenic inflamma-tion in stress-induced termination of murine hair growth is promoted bynervegrowthfactor.Am. J. Pathol. 165, 259-271.
108. Ramsook, C. B., Tan, C., Garcia, M. C., Fung, R., Soybelman, G., Henry, R., Litewka, A., O'Meally, S., Otoo, H. N., Khalaf, R. A., Dranginis, A. M., Gaur, N. K., Klotz, S. A., Rauceo, J. M., Jue, C. K., and Lipke, P. N. (2010). Yeast cell adhesion molecules have functional amyloid-forming sequences. Eukaryotic Cell 9, 393-404.
109. Raychaudhuri, S. P., Farber, E. M., and Raychaudhuri, S. K. (2000). Role of nerve growth factor in RANTES expression by keratinocytes. Acta Derm. Venereol. 80, 247-250.
110. Repetto, E., Yoon, I. S., Zheng, H., and Kang, D. E. (2007). Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J. Biol. Chem. 282, 31504-31516.
111. Rochet, J. C., and Lansbury, P. T. Jr. (2000). Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60-68.
112. Rocken, C., Schwotzer, E. B., Linke, R. P., and Saeger,W. (1996). The classifica-tion of amyloid deposits in clinico-pathological practice. Histopathology 29, 325-335.
113. Rosen, D. R. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amy-otrophic lateral sclerosis. Nature 364, 362.
114. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stähelin, H. B., Hartman, R., and Gharabawi, M. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: interna-tional randomised controlled trial. BMJ 318, 633-638.
115. Samii, A., Nutt, J. G., and Ransom, B. R. (2004). Parkinson's disease. Lancet 363, 1783-1793.
116. Schwendiman, M. N., Beachkofsky, T. M., Wisco, O. J., Owens, N. M., and Hodson, D. S. (2009). Primary cutaneous nodular amyloidosis: case report and review of the literature. Cutis 84, 87-92.
117. Selkoe, D. J. (1994). Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53, 438-447.
118. Shibata, N., Hirano, A., Kobayashi, M., Sasaki, S., Kato, T., Matsumoto, S., Shiozawa, Z., Komori, T., Ike-moto, A., and Umahara, T. (1994). Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 179, 149-152.
119. Sipe, J. D., and Cohen, A. S. (2000). Review: history of the amyloid fibril. J. Struct. Biol. 130, 88-98.
120. Slominski, A., Wortsman, J., Luger, T., Paus, R., and Solomon, S. (2000). Corticotropin releasing hormone and proopiomelanocortin involve-ment in the cutaneous response to stress. Physiol. Rev. 80, 979-1020.
121. Soininen, H., Syrjanen, S., Heinonen, O., Neittaanmäki, H., Miettinen, R., Paljärvi, L., Syrjänen, K., Beyreuther, K., and Riekkinen, P. (1992). Amy-loid beta-protein deposition in skin of patients with dementia. Lancet 339, 245.
122. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
123. Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Acker-ley, S., Durnall, J. C., Williams, K. L., Buratti, E., Baralle, F., de Belleroche, J., Mitchell, J. D., Leigh, P. N., Al-Chalabi, A., Miller, C. C., Nicholson, G., and Shaw, C. E. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672.
124. Stefani, M., and Dobson, C. M. (2003). Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and bio-logical evolution. J. Mol. Med. 81, 678-699.
125. Steinkraus, V., Steinfath, M., Stöve, L., Körner, C., Abeck, D., and Mensing, H. (1993). Beta-adrenergic recep-tors in psoriasis: evidence for down-regulation in lesional skin.Arch. Dermatol. Res. 285, 300-304.
126. Suzuki, M., Mikami, H., Watanabe, T., Yamano, T., Yamazaki, T., Nomura, M., Yasui, K., Ishikawa, H., and Ono, S. (2010). Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol. Scand. 122, 367-372.
127. Takahashi, M., Hoshii, Y., Kawano, H., Gondo, T., Ishihara, T., and Isobe, T. (1996). Ultrastructural evidence for colocalization of kappa light chain-and beta 2-microglobulin-derived amyloids using double labelling immunogold electron microscopy. Virchows Arch. 429, 383-388.
128. Tamaoka, A., Matsumoto, S., Ono, S., Shimizu, N., and Shogi, S. (2000). Increased amyloid beta protein in the skin of patients with amy-otrophic lateral sclerosis. J. Neurol. 247, 633-635.
129. Tillement, J. P., Lecanu, L., and Papadopoulos,V. (2009). Amyloido-sis and neurodegenerative diseases: current treatments and new phar-macological options. Pharmacology 85, 1-17.
130. Tournoy, J., Bossuyt, X., Snellinx, A., Regent, M., Garmyn, M., Serneels, L., Saftig, P., Craessaerts, K., De Strooper, B., and Hartmann, D. (2004). Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum. Mol. Genet. 13, 1321-1331.
131. Trenkwalder, C., Kies, B., Rudzinska, M., Fine, J., Nikl, J., Honczarenko, K., Dioszeghy, P., Hill, D., Ander-son, T., Myllyla, V., Kassubek, J., Steiger, M., Zucconi, M., Tolosa, E., Poewe, W., Surmann, E., White-sides, J., Boroojerdi, B., Chaud-huri, K. R., and Recover Study Group. (2011). Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord. 26, 90-99.
132. Urpe, M., Buggiani, G., and Lotti, T. (2005). Stress and psychoneuroim-munologic factors in dermatology. Dermatol. Clin. 23, 609-617.
133. Vincenti, M. P., and Brinckerhoff, C. E. (2007). Signal transduc-tion and cell-type specific regu-lation of matrix metalloproteinase gene expression: can MMPs be good for you? J. Cell. Physiol. 213, 355-364.
134. von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E. M., and Mandelkow, E. (2000). Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl. Acad. Sci. U.S.A. 97, 5129-5134.
135. Wang, X., Smith, D. R., Jones, J. W., and Chapman, M. R. (2007). In vitro polymerization of a func-tional Escherichia coli amyloid protein. J. Biol. Chem. 282, 3713-3719.
136. Wen, G. Y., Wisniewski, H. M., Blondal, H., Benedikz, E., Frey, H., Pirttila, T., Rudelli, R., and Kim, K. S. (1994). Presence of non-fibrillar amyloid beta protein in skin biopsies of Alzheimer's disease (AD), Down's syndrome and non-AD normal per-sons. Acta Neuropathol. 88, 201-206.
137. West, M. W., Wang, W., Patterson, J., Mancias, J. D., Beasley, J. R., and Hecht, M. H. (1999). De novo amy-loid proteins from designed combi-natorial libraries. Proc. Natl. Acad. Sci. U.S.A. 96, 11211-11216.
138. Westermark, P., Lundmark, K., and Westermark, G. T. (2009). Fib-rils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during inflamma-tion in an animal model. PLoS ONE 4, e6041. doi:10.1371/jour-nal.pone.0006041
139. Winblad, B., Cummings, J., Andreasen, N., Grossberg, G., Onofrj, M., Sadowsky, C., Zechner, S., Nagel, J., and Lane, R. (2007a). A six-month double-blind, randomized, placebo-controlled study of a trans-dermal patch in Alzheimer's dis-ease rivastigmine patch versus cap-sule. Int. J. Geriatr. Psychiatry 22, 456-467.
140. Winblad, B., Kawata, A. K., Beuste-rien, K. M., Thomas, S. K., Wimo, A., Lane, R., Fillit, H., and Blesa, R. (2007b). Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int. J. Geriatr. Psychiatry 22, 485-491.
141. Wolters, E. (2009). Non-motor extran-igral signs and symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S6-S12.
142. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C., Citron, M., and Biere, A. L. (1999). Alpha-synuclein fibril-logenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
143. Xia, X., Qian, S., Soriano, S., Wu, Y., Fletcher, A. M., Wang, X. J., Koo, E. H., Wu, X., and Zheng, H. (2001). Loss of presenilin 1 is asso-ciated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98, 10863-10868.
144. Yanagihara, M., and Mori, S. (1982). Histogenesis of macular amyloido-sis. Nippon Hifuka Gakkai Zasshi 92, 851-859.
145. Zelko, I. N., Mariani, T. J., and Folz, R. J. (2002). Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expres-sion. Free Radic. Biol. Med. 33, 337-349.